Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig

Abstract

Novel biologics that redirect cytotoxic T lymphocytes (CTLs) to kill tumor cells bearing a tumor associated antigen hold great promise in the clinic. However, the ability to safely and potently target CD3 on CTL toward tumor associated antigens (TAA) expressed on tumor cells remains a challenge of both technology and biology. Herein we describe the use of a Half DVD-Ig format that can redirect CTL to kill tumor cells. Notably, Half DVD-Ig molecules that are monovalent for each specificity demonstrated reduced non-specific CTL activation and conditional CTL activation upon binding to TAA compared to intact tetravalent DVD-Ig molecules that are bivalent for each specificity, while maintaining good drug like properties and appropriate PK properties.

Keywords

DVD-Ig / Half DVD-Ig / Halfbody / epidermal growth factor receptor / redirected T-cell cytotoxicity / rCTL

References

[1] Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy . Cancer Res 69:4941–4944

[2] Benjamin JE, Stein AS (2016) The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia . Ther Adv Hematol 7:142–156

[3] Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ (1999) Therapeutic antibody fragments with prolonged in vivo half-lives . Nat Biotechnol 17:780–783

[4] Chatenoud L, Bluestone JA (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity . Nat Rev Immunol 7:622–632

[5] Cheadle EJ (2006) MT-103 Micromet/MedImmune . Curr Opin Mol Ther 8:62–68

[6] Chelius D, Ruf P, Gruber P, Ploscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H (2010) Structural and functional characterization of the trifunctional antibody catumaxomab . MAbs 2:309–319

[7] Dall’Acqua W, Simon AL, Mulkerrin MG, Carter P (1998) Contribution of domain interface residues to the stability of antibody CH3 domain homodimers . Biochemistry 37:9266–9273

[8] Filpula D (2007) Antibody engineering and modification technologies . Biomol Eng 24:201–215

[9] Finco D, Grimaldi C, Fort M, Walker M, Kiessling A, Wolf B, Salcedo T, Faggioni R, Schneider A, Ibraghimov A (2014) Cytokine release assays: current practices and future directions . Cytokine 66:143–155

[10] Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model . Clin Cancer Res 1:1311–1318

[11] Horvath C, Andrews L, Baumann A, Black L, Blanset D, Cavagnaro J, Hastings KL, Hutto DL, MacLachlan TK, Milton M (2012) Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial . Nat Rev Immunol 12:740 (author reply 740)

[12] Ishino T, Wang M, Mosyak L, Tam A, Duan W, Svenson K, Joyce A, O’Hara DM, Lin L, Somers WS (2013) Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics . J Biol Chem 288:16529–16537

[13] Kaufman A, Herold KC (2009) Anti-CD3 mAbs for treatment of type 1 diabetes . Diabetes/Metab Res Rev 25:302–306

[14] Kontermann RE (2011) Strategies for extended serum half-life of protein therapeutics . Curr Opin Biotechnol 22:868–876

[15] Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dorken B, Bargou RC (2000) A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes . Blood 95:2098–2103

[16] Lum LG, Thakur A (2011) Targeting T cells with bispecific antibodies for cancer therapy . BioDrugs 25:365–379

[17] Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D (2010) T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells . Proc Natl Acad Sci 107:12605–12610

[18] McAleese F, Eser M (2012) RECRUIT-TandAbs: harnessing the immune system to kill cancer cells . Future Oncol 8:687–695

[19] Molhoj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA (2007) CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis . Mol Immunol 44:1935–1943

[20] Nagorsen D, Baeuerle PA (2011) Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab . Exp Cell Res 317:1255–1260

[21] Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL (2015) A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells . MAbs 7:584–604

[22] Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age . Nat Rev Immunol 7:715–725

[23] Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C (2015) A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma . Blood 125:4024–4031

[24] Sathish JG, Sethu S, Bielsky MC, de Haan L, French NS, Govindappa K, Green J, Griffiths CE, Holgate S, Jones D (2013) Challenges and approaches for the development of safer immunomodulatory biologics . Nat Rev Drug Discov 12:306–324

[25] Sgro C (1995) Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review . Toxicology 105:23–29

[26] Staerz UD, Bevan MJ (1989) Redirecting the cellular immune response . Int Rev Immunol 4:159–173

[27] Weisser NE, Hall JC (2009) Applications of single-chain variable fragment antibodies in therapeutics and diagnostics . Biotechnol Adv 27:502–520

[28] Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin . Nat Biotechnol 25:1290–1297

[29] Ying T, Chen W, Gong R, Feng Y, Dimitrov DS (2012) Soluble monomeric IgG1 Fc . J Biol Chem 287:19399–19408

RIGHTS & PERMISSIONS

The Author(s) 2017. This article is an open access publication